CD46 and prostate cancer: Li et al. [84] described a YS5-based anti-CD46 antibody labeled with 212Pb (212Pb-TCMC-YS5) in a subcutaneous mCRPC cell line-derived xenograft (CDX), an orthotopically grafted mCRPC CDX model (ortho-CDX), and a prostate cancer patient-derived xenograft model (PDX) [84].